The first twice-daily injectable HIV prevention drug based on lenacapavir has received CHMP recommendation for authorization, promising an effective and affordable solution.
Cristina Petrache
Health
Foto pexels.com
Always see our news on Google
Lenacapavir is the first twice-daily injectable drug for the prevention of HIV infection, with 99.9% efficacy in clinical trials. Recommended by the CHMP, this treatment simplifies prevention by eliminating the need for daily tablets. In Romania, where the cost of HIV treatment is high, the new PrEP could reduce costs and improve access for vulnerable people. Approved at European level, this drug represents a significant opportunity to transform HIV prevention into public health policy.
Sources
Europa se apropie de aprobarea primului tratament PrEP injectabil cu administrare la 6 luni - o şansă uriaşă pentru prevenţia HIV în România
Europa se apropie de aprobarea primului tratament PrEP injectabil cu administrare la 6 luni - o șansă uriașă pentru prevenția HIV în România
Omenirea, mai aproape ca niciodată de a opri virusul HIV. Europa a autorizat tratamentul revoluționar
E.U. regulator approves injectable HIV drug that experts say could help stop transmission
EU regulator approves injectable HIV drug that experts say could help stop transmission
Latest News
18:06
The Romanian Patriarchate criticizes the bill regarding the decriminalization of drug possession for personal use and calls for responsibility
17:50
Victor Ponta asks Ilie Bolojan for the PNL to vote for the future Government led by Luca Niculescu, invoking a “diplomatic way out”
17:50
EU borrowing could reach EUR 1 trillion in 2027, putting pressure on future budgets
17:44
Donald Tusk warns of a “cult of violence” following knife attacks at Polish schools
17:40
France offers farmers interest-free loans of up to two billion euros
See more news
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
